U.S. Markets open in 2 hrs 54 mins

Intercept OCA likely to qualify for accelerated approval, says Oppenheimer

Oppenheimer believes that a recent draft FDA document corroborates its belief that Intercept's OCA treatment will qualify for accelerated approval in primary biliary cirrhosis. The firm raised its price target on the stock to $64 from $60 and keeps an Outperform rating on the stock.